lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the normal menstrual cycle, estradiol levels measure typically <50 pg/mL at menstruation, rise with follicular development (peak: 200 pg/mL), drop briefly at ovulation, and rise again during the luteal phase for a second peak. At the end of the luteal phase, estradiol levels drop to their menstrual levels unless there is a pregnancy. During pregnancy, estrogen levels, including estradiol, rise steadily toward term. The source of these estrogens is the placenta, which aromatizes prohormones produced in the fetal adrenal gland.
Libiguin A is a naturally occurring limonoid found in Neobeguea mahafalensis, a flowering plant found in Madagascar with a long history of traditional medical use. It is a derivative of phragmalin. The compound has been reported to produce highly potent, strong, and long-lasting pro-sexual effects in rodents. The semisynthesis of libiguin A from phragmalin has been described. An analogue also found in Neobeguea mahafalensis, libiguin B, has similar pro-sexual effects but is far less potent in comparison. Another analogue, a synthetic compound known as volufralin (LIB-01; DIC-2024), is under development for the treatment of erectile dysfunction and premature ejaculation. Libiguin A was first described in the scientific literature by 2014.
=== Railex and other unit trains === In 2006 Railex LLC launched service in partnership with the Union Pacific Railroad and CSX between Wallula, Washington, and Rotterdam, New York, followed in 2008 by a Delano, California, to NY line, and Jacksonville, Florida service from the west coast in 2014. Railex runs unit trains of 55 large, "plate F" refrigerated cars. Two additional refrigerated unit-train services were announced in 2013, the Green Express, from Tampa, Florida to Kingsbury, Indiana, operated by CSX and the Tampa Port Authority, and the TransCold Express operated by McKay Transcold, LLC and BNSF, connecting the California Central Valley with the midwest.
=== Biological properties === Despite the promising results in different cell studies and proof of concept studies, there is still incomplete understanding of the full biocompatibility of graphene-based materials. Different cell lines react differently when exposed to graphene, and it has been shown that the lateral size of the graphene flakes, the form and surface chemistry can elicit different biological responses on the same cell line. There are indications that graphene has promise as a useful material for interacting with neural cells; studies on cultured neural cells show limited success. Graphene also has some utility in osteogenesis. Researchers at the Graphene Research Centre at the National University of Singapore (NUS) discovered in 2011 the ability of graphene to accelerate the osteogenic differentiation of human mesenchymal stem cells without the use of biochemical inducers. Graphene can be used in biosensors; in 2015, researchers demonstrated that a graphene-based sensor can be used to detect a cancer risk biomarker. In particular, by using epitaxial graphene on silicon carbide, they were repeatedly able to detect 8-hydroxydeoxyguanosine (8-OHdG), a DNA damage biomarker.
Sources: en.wikipedia.org
Pellagra is a disease caused by a lack of the vitamin niacin (vitamin B3). Symptoms include inflamed skin, diarrhea, dementia, and sores in the mouth. Areas of the skin exposed to friction and radiation are typically affected first. Over time, affected skin may become darker, stiffen, peel, or bleed. The two main types of pellagra are primary and secondary. Primary pellagra is due to a diet that does not contain enough niacin and tryptophan. Secondary pellagra is due to a poor ability to use the niacin within the diet. This can occur as a result of alcoholism, long-term diarrhea, carcinoid syndrome, Hartnup disease, and a number of medications such as isoniazid. Diagnosis is typically based on symptoms and may be assisted by urine testing. Treatment is with either nicotinic acid or nicotinamide supplementation. Improvements typically begin within a few days. General improvements in diet are also frequently recommended. Decreasing sun exposure via sunscreen and proper clothing is important while the skin heals. Without treatment, death may occur. The disease occurs most commonly in the developing world, often as a disease of poverty associated with malnutrition, specifically sub-Saharan Africa.
=== Diagnostic biomarkers === Guidelines outlining requirements for inclusion of soluble biomarkers in osteoarthritis clinical trials were published in 2015, but there are no validated biomarkers used clinically to detect osteoarthritis, as of 2021. A 2015 systematic review of biomarkers for osteoarthritis, looking for molecules that could be used for risk assessments, found 37 different biochemical markers of bone and cartilage turnover in 25 publications. The strongest evidence was for urinary C-terminal telopeptide of type II collagen (uCTX-II) as a prognostic marker for knee osteoarthritis progression, and serum cartilage oligomeric matrix protein (COMP) levels as a prognostic marker for incidence of both knee and hip osteoarthritis. A review of biomarkers in hip osteoarthritis also found associations with uCTX-II. Procollagen type II C-terminal propeptide (PIICP) levels reflect type II collagen synthesis in body and within joint fluid PIICP levels can be used as a prognostic marker for early osteoarthritis.
Classifying Datura as to its species is difficult, and the descriptions of new species often are accepted prematurely. Later, these "new species" are found to be simply varieties that have evolved due to conditions at a specific location. These new designations usually disappear in a few years. Contributing to the confusion is the fact that various species, such as D. wrightii and D. innoxia, are very similar in appearance, and the variation within a species can be extreme. For example, Datura species can change size of plant, leaf and flowers, all depending on location. The same species, when growing in a half-shady, damp location, can develop into a flowering bush 80 cm (30 in) in height, but when growing in a very dry location, will only grow into a thin plant not much more 13 cm (5 in), with tiny flowers and a few miniature leaves. Datura species are native to dry, temperate and subtropical regions. Most species are native to Mexico, which is considered the centre of origin of the genus. Several species are considered to have extra-American native ranges: D. ferox (native to China), D. metel (native to India and Southeast Asia) and D. leichardthii (native to Australia); however, these may be early introductions from Central America.
Sources: en.wikipedia.org
The US Navy dispatched two naval battle groups built around the aircraft carriers USS Dwight D. Eisenhower and USS Independence to the Gulf, where they were ready by 8 August. The US sent the battleships USS Missouri and USS Wisconsin. 48 US Air Force F-15s from the 1st Fighter Wing at Langley Air Force Base, Virginia, landed in Saudi Arabia and commenced round-the-clock air patrols of the Saudi–Kuwait–Iraq border to discourage Iraqi military advances. They were joined by 36 F-15 A-Ds from the 36th Tactical Fighter Wing at Bitburg, Germany. The Bitburg contingent was based at Al Kharj Air Base. The 36th TFW would be responsible for 11 confirmed Iraqi Air Force aircraft shot down during the war. Two Air National Guard units were stationed at Al Kharj Air Base, the South Carolina Air National Guard's 169th Fighter Wing flew bombing missions with 24 F-16s flying 2,000 combat missions and dropping four million pounds (1,800,000 kilograms; 1,800 metric tons) of munitions, and the New York Air National Guard's 174th Fighter Wing from Syracuse flew 24 F-16s on bombing missions. Military buildup continued, reaching 543,000 troops, twice that used in the 2003 invasion. Much of the material was airlifted or carried to the staging areas via fast sealift ships, allowing a quick buildup. Amphibious exercises were carried out in the Gulf, including Operation Imminent Thunder, which involved the USS Midway and 15 other ships, 1,100 aircraft, and a thousand Marines.
== Fragments == Big dynorphin1-32 is the primary endogenously documented big dynorphin form, but various shorter big dynorphin fragments have been synthesized for research purposes. These include (2-32), (2-26), (9-19) forms.
== Reform and replacement == The Local Transport Act 2008 reconstituted it as the Greater Manchester Integrated Transport Authority. The integrated transport authority was replaced by Transport for Greater Manchester in 2011, which is accountable to the Greater Manchester Combined Authority.
Florey became the President of the Royal Society on 30 November 1960. Since 1873, the Royal Society had occupied Burlington House. While it had a sumptuous Meeting Room and Council Room, the administrative staff, who numbered about seventy in 1960, worked in cramped conditions in the awkward-to-access offices in the attic and basement. Florey decided to seek better accommodation. In December 1960, Florey was informed that plans to build new accommodation for the Foreign Office at Carlton House Terrace had fallen though and that the Crown Estate Commissioners had suggested that the premises might be suitable for the headquarters of cultural bodies. Florey inspected the property and lodged a formal application to occupy four houses on the site, numbers 6 to 9. Florey raised the money required to realise the architect Sir William Holford's vision for the interiors. While the government paid the rent and upkeep on the Royal Society's accommodation, about £45,000 in 1963 (equivalent to £822,000 in 2025), repairs and alterations were at the Royal Society's expense and ultimately came to around £850,000 (equivalent to £15,525,000 in 2025). The move was not completed during Florey's term of office; the new building was opened by Queen Elizabeth II on 21 November 1967. Florey pursued a more progressive and internationalist outlook for the Royal Society. He hosted Yuri Gagarin at a luncheon at Burlington House, and led Royal Society visits to Russia in 1965 and 1967.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.